Ranking
Tirzepatide Pharmacy Transparency Rankings
Pharmacy transparency measures whether a provider discloses, before you pay, which pharmacy compounds your medication, its state licence, facility type, and the preparation's concentration. No provider in the current dataset has had these disclosures verified, so no ranking is published — an empty ranking is the correct output when the underlying facts are unverified.
Key takeaways
- Transparency means disclosing pharmacy identity, licence, facility type, and concentration before purchase.
- No provider in the dataset has had these disclosures verified first-party.
- No ranking is published rather than ordering providers on unverified claims.
- These are the disclosures most worth demanding, because they are independently checkable.
- A provider's willingness to answer before payment is itself informative.
| Providers assessed | 24 in the current dataset |
|---|---|
| Providers with verified pharmacy disclosure | 0 |
| Ranking published | No — insufficient verified data |
| Criteria when data exists | Pre-enrolment disclosure of identity, licence, facility type, concentration |
| Methodology | v1.0 |
What would a transparent provider disclose before payment?
The compounding pharmacy's legal name; the state in which it is licensed and its licence number; whether it is a 503A pharmacy or 503B outsourcing facility; the preparation's concentration in mg/mL; and the beyond-use date policy. Each of these is independently checkable, which is exactly why they are the right criteria — they cannot be satisfied with reassuring language.
Disclosures that cannot be checked, such as claims about quality or purity without a verifiable source, do not count.
Why rank transparency rather than quality?
Because quality of a compounded preparation cannot be assessed from outside — it would require testing individual vials for content and sterility, which no publication can do at scale. Transparency is a proxy: it measures whether a provider gives you the information needed to perform the checks that are possible.
It is an imperfect proxy. A transparent provider could still use a poor pharmacy. But an opaque provider prevents you from finding out either way.
- Ask for the compounding pharmacy's legal name before paying.
- Ask for the state licence number and state of licensure.
- Ask whether it is 503A or 503B.
- Ask for the concentration in mg/mL.
- Ask for the beyond-use date policy on multi-month supplies.
- Note whether answers come before or only after enrolment.
What the evidence shows
- That pharmacy disclosure criteria are independently checkable when provided.
What the evidence does not show
- Any transparency ranking — the underlying disclosures are unverified.
- That transparency guarantees preparation quality.
Related: Verification method · Provider transparency ranking
What exactly differs between approved and compounded tirzepatide?
| Attribute | FDA-approved (Zepbound / Mounjaro) | Compounded tirzepatide |
|---|---|---|
| Premarket FDA review | Yes — safety, efficacy, and quality reviewed | No |
| Randomised trial evidence | SURMOUNT and SURPASS programmes | None identified |
| Concentration | Fixed and verified by the manufacturer | Varies by pharmacy; not independently verified |
| Presentation | Fixed-dose pen or autoinjector | Commonly a vial requiring measurement |
| Dating | Manufacturer expiry from stability testing | Pharmacy-assigned beyond-use date |
| Adverse-event capture | Systematic post-marketing surveillance | Less systematic |
| Consumer verification route | FDA approval record | State board licence lookup |
| Group | FDA-approved | Compounded |
|---|---|---|
| Randomised trials | 6 | 0 |
| Verified concentration | 1 | 0 |
| Premarket review | 1 | 0 |
What does the regulatory framework actually say?
Compounding occupies a specific legal position that is frequently described inaccurately in marketing. A 503A pharmacy prepares patient-specific preparations against individual prescriptions and is licensed by a state board of pharmacy. A 503B outsourcing facility may prepare larger batches without individual prescriptions, registers with the FDA, and is subject to current good manufacturing practice requirements. Neither route produces an FDA-approved product.
That last sentence is the one most often blurred. Registration is not approval. Inspection is not approval. Operating legally is not approval. Approval is a specific determination that the FDA has reviewed evidence of safety, effectiveness, and manufacturing quality for a particular product before it is marketed, and no compounded preparation has been through that process.
| Term | What it actually means | What it does not mean |
|---|---|---|
| FDA approved | The agency reviewed safety, efficacy and quality evidence before marketing | Applies to any compounded preparation |
| FDA registered | The facility filed a registration with the agency | The product was reviewed or approved |
| FDA inspected | The agency conducted a facility inspection | The product was approved, or that the inspection found no problems |
| State licensed | A state board authorised the pharmacy to operate | Any federal review of the product |
| cGMP compliant | The facility follows manufacturing practice standards | The specific product was evaluated for safety or efficacy |
| Third-party tested | A laboratory analysed a sample | Systematic batch verification, unless the scope and frequency are disclosed |
What can a patient actually verify before paying?
Where randomised evidence is absent, verification of the supply chain takes its place as the meaningful check. The useful feature of these checks is that they are all things a reader can do independently, against public records, before any money changes hands.
| Check | How to do it | What a refusal or gap tells you |
|---|---|---|
| Pharmacy legal name | Ask the provider in writing before enrolling | A provider unwilling to name its pharmacy is withholding the single most useful fact |
| State licence | Search the licensing state board's public register | An unlisted or lapsed licence is disqualifying |
| 503A or 503B status | Ask, then check the FDA outsourcing facility register for 503B claims | A 503B claim absent from the register is a serious discrepancy |
| Disciplinary history | State board records and enforcement notices | Prior action is not automatically disqualifying but is material |
| Concentration in mg/mL | Ask before ordering; confirm on the dispensing label | An unwillingness to state concentration makes safe use impossible |
| Beyond-use date policy | Ask what date is assigned and on what basis | No stated policy suggests weak quality systems |
| Cold-chain and excursion policy | Ask who bears risk if a shipment arrives warm | No policy means the risk sits with you |
A provider that answers all seven readily has demonstrated something meaningful. One that treats these as intrusive has also answered, in a different way. This is not a guarantee of quality — it is the strongest signal available to a consumer in a market where the usual guarantee, regulatory approval, does not exist.
What are the limits of what this page can tell you?
This page describes a regulatory framework and a verification method. Both have limits that matter.
- Regulatory status changes, and enforcement priorities change with it. Statements here carry the verification date shown above.
- State licensing requirements differ, so a check that is straightforward in one state may be harder in another.
- Verification of a pharmacy's licence establishes that it is authorised to operate. It does not establish the quality of any particular preparation.
- No verification step available to a consumer substitutes for the premarket review that approved products undergo.
What does this page cover, and what does it deliberately leave out?
This page addresses Disclosure, legal identity, license, facility and formulation and sample, organised around the primary question of tirzepatide pharmacy transparency. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Disclosure | Covered on this page | Regulatory or policy source |
| Legal identity | Covered on this page | Regulatory or policy source |
| License | Covered on this page | Regulatory or policy source |
| Facility | Covered on this page | Regulatory or policy source |
| Formulation and sample | Covered on this page | Regulatory or policy source |
| Individualized clinical instruction | Deliberately not covered | Belongs with the state board of pharmacy and the provider |
What are the limits of what this page can tell you?
Every page on this site rests on a specific pharmacy verification record, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for the state board of pharmacy and the provider.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
Any of the following would change what this page concludes:
- New primary evidence bearing directly on tirzepatide pharmacy transparency.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
What do the technical terms on this page mean?
Definitions for the 5 technical terms this page uses, including 503A, 503B, beyond-use date, compounded — in the specific sense used above.
| 503A | A pharmacy that compounds patient-specific preparations against individual prescriptions. It is licensed by a state board of pharmacy and is not subject to the same federal manufacturing requirements as a 503B facility. |
|---|---|
| 503B | An outsourcing facility that may compound in larger batches without individual prescriptions. It registers with the FDA and is subject to current good manufacturing practice requirements, though registration is still not product approval. |
| beyond-use date | The date after which a compounded preparation should not be used. It is assigned by the compounding pharmacy based on its own conditions, and is typically much shorter than a manufacturer expiry date derived from formal stability testing. |
| compounded | Prepared by a pharmacy rather than manufactured under an approved application. Compounded tirzepatide is not FDA approved and has not been evaluated in any randomised trial. |
| mg/mL | Milligrams of drug per millilitre of liquid — the concentration. Two vials containing the same nominal dose can require different injection volumes if their concentrations differ, which is why this site does not publish volume calculations. |
Frequently asked questions
Which provider is most transparent about its pharmacy?
Not established. No provider's pharmacy disclosure has been verified first-party, so no ranking is published.
What should a provider tell me before I pay?
Pharmacy legal name, state licence number, 503A or 503B status, concentration in mg/mL, and beyond-use date policy.
Does transparency mean the product is good?
No. It means you can perform the checks that are possible. An opaque provider prevents that entirely.
Why not rank on marketing claims?
Because unverified claims formatted as a ranking become false verification.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.